A phase II study of S-1 in combination with sorafenib in metastatic renal cell carcinoma

被引：0
|
作者：
Sakai, Hideki
Ohba, Kojiro
Hashine, Katsuyoshi
Tomita, Yoshihiko
Shinohara, Nobuo
Fujisawa, Masato
Eto, Masatoshi
Ozono, Seiichiro
Tsukamoto, Taiji
Akaza, Hideyuki
Naito, Seiji
机构：
[1] Nagasaki Univ, Dpartment Nephrourol, Grad Sch Biomed Sci, Nagasaki 852, Japan
[2] Natl Hosp Org Shikoku Canc Ctr, Dept Urol, Matsuyama, Ehime, Japan
[3] Yamagata Univ, Sch Med, Dept Urol, Yamagata 99023, Japan
[4] Hokkaido Univ, Dept Urol, Grad Scohool Med, Sapporo, Hokkaido, Japan
[5] Kobe Univ, Dept Urol, Grad Sch Med, Kobe, Hyogo 657, Japan
[6] Kumamoto Univ, Dept Urol, Fac Life Sci, Kumamoto, Japan
[7] Hamamatsu Univ Sch Med, Dept Urol, Hamamatsu, Shizuoka 4313192, Japan
[8] Sapporo Med Univ, Dept Urol, Sch Med, Sapporo, Hokkaido, Japan
[9] Univ Tokyo, Res Ctr Adv Sci & Technol, Tokyo, Japan
[10] Kyushu Univ, Dept Urol, Grad Sch Med Sci, Fukuoka 812, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.529
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
529
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study
    Matsubara, Nobuaki
    Naito, Yoichi
    Nakano, Kenji
    Fujiwara, Yutaka
    Ikezawa, Hiroki
    Yusa, Wataru
    Namiki, Masayuki
    Okude, Takashi
    Takahashi, Shunji
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 (11) : 922 - 928
  • [42] Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
    Bhatia, Shailender
    Curti, Brendan
    Ernstoff, Marc S.
    Gordon, Michael
    Heath, Elisabeth I.
    Miller, Wilson H., Jr.
    Puzanov, Igor
    Quinn, David I.
    Flaig, Thomas W.
    VanVeldhuizen, Peter
    Byrnes-Blake, Kelly
    Freeman, Jeremy A.
    Bittner, Rachel
    Hunder, Naomi
    Souza, Sonia
    Thompson, John A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2014, 2
  • [43] Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma
    S R Park
    H K Kim
    C G Kim
    I J Choi
    J S Lee
    J H Lee
    K W Ryu
    Y-W Kim
    J-M Bae
    N K Kim
    British Journal of Cancer, 2008, 98 : 1305 - 1311
  • [44] Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma
    Ohtsu A.
    Baba H.
    Sakata Y.
    Mitachi Y.
    Horikoshi N.
    Sugimachi K.
    Taguchi T.
    British Journal of Cancer, 2000, 83 (2) : 141 - 145
  • [45] A phase I/II study of gemcitabine (GEM) with oral S-1 in metastatic pancreatic carcinoma.
    Nakamura, K
    Yamaguchi, T
    Ishihara, T
    Ishiguro, H
    Kabayashi, A
    Tadenuma, H
    Saisyo, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 346S - 346S
  • [46] Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma
    Ohtsu, A
    Baba, H
    Sakata, Y
    Mitachi, Y
    Horikoshi, N
    Sugimachi, K
    Taguchi, T
    BRITISH JOURNAL OF CANCER, 2000, 83 (02) : 141 - 145
  • [47] Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC): A phase II study, preliminary results
    Tomasello, L.
    Sertoli, M. R.
    Rubagotti, A.
    Guglielmini, P.
    Tacchini, L.
    Bedognetti, D.
    Ricci, F.
    Sanguineti, S.
    Cassata, A.
    Boccardo, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] A phase II study of thalidomide in advanced metastatic renal cell carcinoma
    Minor, DR
    Monroe, D
    Damico, LA
    Meng, G
    Suryadevara, U
    Elias, L
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (04) : 389 - 393
  • [49] Phase II study of lenalidomide in patients with metastatic renal cell carcinoma
    Choueiri, Toni K.
    Dreicer, Robert
    Rini, Brian I.
    Elson, Paul
    Garcia, Jorge A.
    Thakkar, Snehal G.
    Baz, Rachid C.
    Mekhail, Tarek M.
    Jinks, Holly A.
    Bukowski, Ronald M.
    CANCER, 2006, 107 (11) : 2609 - 2616
  • [50] Phase II study of vinflunine in patients with metastatic renal cell carcinoma
    D. Goldstein
    S. P. Ackland
    D. R. Bell
    I. N. Olver
    I. D. Davis
    M. A. Rosenthal
    G. C. Toner
    M. C. Pinel
    M. Byrne
    Investigational New Drugs, 2006, 24 : 429 - 434
12345